Please assess the completion status of the following clinical trial:

Trial Title: Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have histologically or cytologically confirmed prostate cancer.~2. Patients must have localized prostate cancer and have decided to undergo a prostatectomy or brachytherapy.~3. Patient must not be taking supplemental vitamin E.~4. Age \>18 years.~5. Life expectancy of greater than 6 months.~6. ECOG performance status =\< 2.~7. Patients must have normal organ and marrow function as defined below:~   * leukocytes \>= 3,000/mcL~  * absolute neutrophil count \>=1,500/mcL~  * platelets \>=100,000/mcL~  * total bilirubin within normal institutional limits~  * AST/ALT =\< 2.5 X institutional upper limit of normal~  * creatinine =\< 1.5 X normal institutional upper limit of normal~  * INR =\<1.4~  * PTT =\<1.4 X institutional upper limit of normal~8. Patients must have the ability to understand, and the willingness to sign a written informed consent document.~Exclusion Criteria:~1. Patients who have metastatic prostate cancer.~2. Patients may not be receiving any other investigational agents.~3. Patients with a known bleeding diathesis or patients on therapeutic anticoagulation. (This does not include the use of aspirin but refers to warfarin, heparin, or low molecular weight heparins).~4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to vitamin E.~5. The patient may not receive a gonadotrophin release agonist (such as goserelin, or leuprolide), or an antiandrogen (such as bicalutamide, flutamide, or nilutamide) during the study.~6. Uncontrolled intercurrent illness that would limit compliance with study requirements.~   * Inclusion of Women and Minorities~     * Only men are eligible for this trial. Members of all races and ethnic groups are eligible for this trial.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Vitamin E) (Type: EXPERIMENTAL): Vitamin E
- Arm 2 (Type: PLACEBO_COMPARATOR): Placebo (same vehicle as used for vitamin E)

Based on this trial design, predict the completion outcome and termination type (if applicable).